long intergenic non-protein coding RNA 664Genealiases: []
Q-omics provides the consensus-scored LINC00664 profile across patient tissues and cancer cell-line models. LINC00664 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC00664 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, LINC00664 RNA expression shows 15,076 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where LINC00664 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00664 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00664 survival associations across molecular data types. LINC00664 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00664 RNA expression–survival associations across cancer types. High LINC00664 expression shows unfavorable associations in KIRC, KICH and LUSC, but favorable associations in OV, SKCM and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC00664 RNA expression.
This table summarizes LINC00664 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00664. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00664 shows lower tumor expression in LUSC and higher tumor expression in KIRC, KIRP, BRCA, LIHC and LUAD. The KIRC box plot shows higher LINC00664 RNA expression in tumor versus normal tissue (log2 FC = +0.294, t-test p < 0.001).
This table shows molecular features associated with LINC00664 in patient tissues and cancer cell lines. In patient samples, LINC00664 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
